Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
This Finnish nationwide study demonstrates that patients with atrial flutter have a substantially lower risk of ischaemic stroke compared to those with atrial fibrillation, highlighting important differences in thromboembolic risk profiles
The NOTION-4 trial demonstrates that 3 months of DOAC therapy post-TAVR reduces early HALT incidence compared to SAPT, but benefits diminish after discontinuation, highlighting nuanced balance between thrombosis prevention and bleeding risk
This article reviews the accelerated evidence generation for anticoagulation in noncritically ill COVID-19 patients, highlighting how coordinated trials and data sharing influenced clinical guidelines and patient outcomes during the pandemi
In frail elderly Asian AF patients stable on warfarin, transitioning to DOACs increased risks of bleeding, thromboembolic events, and mortality, emphasizing cautious individualized management.
A multicomponent stewardship intervention significantly reduced inappropriate antiplatelet prescription among patients on DOACs, decreasing bleeding risk, particularly in stable coronary artery disease.
The VISION Cardiac Surgery cohort found POAF in about one-third of patients, with wide variation in discharge treatment. POAF strongly predicted later atrial fibrillation and was associated with higher 1-year mortality.
A survey study found three distinct patient preference patterns for anticoagulation after hip or knee replacement: clot-prevention focused, balanced, and cost-focused. These differences may help personalize postoperative blood thinner choic
A survey study found three distinct patient preference patterns for anticoagulation after hip or knee replacement, highlighting the importance of shared decision-making based on clot risk, bleeding risk, and cost.
Subgroup analysis of the OPTIMAS trial reveals that neither the timing of atrial fibrillation diagnosis nor AF subtype modifies the treatment effect of early versus delayed direct oral anticoagulant initiation in acute ischemic stroke. Pers
The ESC EORP ROPAC III registry highlights a stark contrast in pregnancy outcomes between mechanical and biological heart valves, revealing that only 54% of women with mechanical valves achieve an uncomplicated live birth, largely due to an
The APERITIF randomized clinical trial found that adding low-dose rivaroxaban to dual antiplatelet therapy (DAPT) did not significantly reduce the incidence of left ventricular thrombus at one month in anterior STEMI patients, while signifi
A multicentre RCT in China found that pharmacist-led patient self-testing (PST) significantly improves time in therapeutic range and reduces major bleeding and thromboembolism in patients with mechanical heart valves compared to traditional
The ROXI-VTE trials demonstrate that inhibiting the Factor XI catalytic domain significantly reduces postoperative VTE compared to enoxaparin. While blocking Factor XIIa-mediated activation showed promise, it failed to meet superiority, hig
A large-scale study of 144,969 Medicare beneficiaries reveals that initial anticoagulant prescriptions for atrial fibrillation may not reduce ischemic stroke risk in patients over 66, while significantly increasing major bleeding hazards, s
A longitudinal study reveals that over 5% of patients with MCI or dementia develop new indications for anticoagulants or thrombolytics within a year, complicating the use of anti-amyloid monoclonal antibodies due to increased intracranial h
A large-scale cohort study reveals that while rivaroxaban and apixaban offer similar protection against limb events and stroke in patients with AF and PAD, rivaroxaban is associated with a 55% higher risk of major bleeding, suggesting apixa
A large European cohort study reveals that while women with atrial fibrillation are less likely to receive anticoagulants and show higher crude thromboembolism rates, female sex is not an independent risk factor after adjusting for comorbid
In patients who underwent successful catheter ablation for atrial fibrillation at least one year earlier, rivaroxaban did not significantly reduce the composite of clinical or covert embolic stroke compared with aspirin over 3 years, while
A 3-center randomized pilot trial found that randomized allocation to low- versus moderate-intensity anticoagulation during venovenous ECMO is feasible, with lower major bleeding rates in the low-intensity arm and no clear excess of thrombo
The CIRROXABAN trial evaluates rivaroxaban’s efficacy and safety in preventing complications of portal hypertension in cirrhotic patients, suggesting improved complication-free survival without significantly increasing major bleeding